Rybrevant (amivantamab-vmjw), Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) Coverage Criteria
Customize your policy alerts
Sign up for Empire Bluecross Policy CC-0201 alerts
Get alerted when Policy CC-0201 changes without checking for updates manually.
Monitor payer policy activity
This policy governs medical-benefit coverage and prior authorization for amivantamab-vmjw and amivantamab/hyaluronidase-lpuj in adults and individuals under 19 with specified recurrent, advanced, locally advanced, or metastatic non-small cell lung cancer. Coverage requires the applicable EGFR mutation, disease status, prior-treatment history, and combination or single-agent regimen described in the criteria.
The criteria now refer to progression on amivantamab in any formulation and clarify disease progression on or after EGFR tyrosine kinase inhibitor treatment.
The policy added a step-therapy requirement for Rybrevant Faspro.
The policy revised coding by removing HCPCS C9999 and J9999 for Rybrevant Faspro and adding HCPCS J9062.
The policy added coverage criteria for Rybrevant and Rybrevant Faspro in NSCLC with brain metastases.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.